Quick Answer
Caribou Biosciences, Inc. reported R&D Expense of $109.44 million for fiscal year 2025.
Caribou Biosciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $109.44M | -15.9% |
| 2024 | $130.15M | +16.1% |
| 2023 | $112.08M | +36.3% |
| 2022 | $82.23M | +57.4% |
| 2021 | $52.26M | +51.8% |
| 2020 | $34.42M | +45.7% |
| 2019 | $23.64M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $22.40M | -26.4% | -19.1% |
| June 30, 2025 | $27.69M | -22.0% | -22.1% |
| March 31, 2025 | $35.53M | +5.2% | +16.8% |
| September 30, 2024 | $30.42M | +6.4% | -14.3% |
| June 30, 2024 | $35.48M | +33.9% | +5.0% |
| March 31, 2024 | $33.79M | +31.4% | +18.2% |
| September 30, 2023 | $28.58M | +43.0% | +7.9% |
| June 30, 2023 | $26.50M | +17.4% | +3.1% |
- Caribou Biosciences, Inc. showed a decrease of -15.9% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Caribou Biosciences, Inc.’s r&d expense has grown by 363.0% (from $23.64 million to $109.44 million).
- The most recent figure is from Caribou Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: